血浆中和肽素、N-末端脑钠肽前体水平对慢性心力衰竭患者生存质量的评估价值  

Plasma levels of copeptin and N-terminal pro-brain natriuretic peptide for evaluating the quality of life in patients with chronic heart failure

作　　者：包浔娜[1] 唐方明[1] 陈冠鹏[1] 何星球[1] 

机构地区：[1]广东省农垦中心医院心血管内科,广东湛江524002

出　　处：《广东医学院学报》2016年第5期453-455,458,共4页Journal of Guangdong Medical College

摘　　要：目的探讨血浆中和肽素、N-末端脑钠肽前体(NT-proBNP)水平在慢性心力衰竭患者预后及生存质量的预测价值。方法检测460例慢性心力衰竭患者入院时血浆中和肽素及NT-proBNP水平,并分为A组220例(和肽素≥14.36pmol/L或NT-proBNP≥1923.90 ng/L)和B组240例(和肽素<14.36 pmol/L且NT-proBNP<1923.90 ng/L),比较两组患者出院后1 a预后、生存质量、心功能指标差异。结果入院时A组的心功能分级明显较B组差(P<0.01)。出院1 a后B组的左室射血分数、左室舒张末期内径、左室收缩末期内径、6 min步行距离均显著优于A组(P<0.01),心理、生理、社会评分均显著高于A组(P<0.01),心衰复发率和心脏相关死亡率明显低于A组(P<0.01或0.05)。结论慢性心力衰竭患者血浆中和肽素、NT-proBNP水平过高可能预示后期生存质量、心功能恢复较差。Objective To study the predictive value of plasma copeptin and N- terminal pro-brain natriuretic peptide（NTproBNP） levels for prognosis and quality of life（QOL） in patients with chronic heart failure（CHF）. Methods Plasma copeptin and NT-proBNP contents were detected in 460 cases of CHF on admission. These patients were divided into Group A（n=220; copeptin ≥ 14.36 pmol/L or NT-proBNP ≥1923.90 ng/L） and Group B（n=240; copeptin 〈14.36 pmol/L and NT-proBNP 〈1923.90 ng/L）. Prognosis, QOL, and cardiac parameters were compared between two groups one year after discharge. Results Heart function grades on admission were lower in Group A than in Group B（P〈0.01）. Compared with Group A, left ventricular ejection fraction（LVEF）, left ventricular end-diastolic and end-systolic diameter, 6-min walking distance, and psychological, physiology and social scores were increased（P〈0.01）, but recurrent heart failure and heartrelated mortality were decreased（P〈0.01-0.05） in Group B after one year. Conclusion The upregulation of plasma copeptin and NT-proBNP levels may predict the poor QOL and cardiac function recovery in patients with CHF.

关 键 词：和肽素 N-末端脑钠肽前体 慢性心力衰竭 生存质量 

分 类 号：R541.6[医药卫生—心血管疾病]